Extracorporeal Membrane Oxygenation (ECMO) for COVID-19 patients with ARDS

I. Assessment

A. Policy and Research Question

Policy Question:

Should ECMO for COVID-19 patients with acute respiratory distress syndrome (ARDS) be recommended for use and covered by PhilHealth? 

          Research Questions:

Treatment guidelines and evidence synthesis on the use of ECMO

1. 1. 1. Which country/countries have implemented ECMO for the management of ARDS secondary to COVID-19 infection?
      2. What is the current position/ recommendation of HTA agencies regarding the use of ECMO for the management of ARDS secondary to COVID-19 infection?

Clinical efficacy / effectiveness and safety

Among critically ill COVID-19 patients with acute respiratory distress syndrome, is ECMO alone or combined with mechanical ventilation compared to mechanical ventilation alone effective and safe in improving the survival rate, decreasing the hospitalization days, resolving the symptoms and decreasing the incidence of adverse events?

Resource requirements

What are the technical, infrastructure, logistical and organizational needs in implementing ECMO for COVID-19 patients with ARDS?

B. Protocol: Not available.

C. Reviewers: Health Technology Assessment Unit, DOH

D. Start of Review: July 24, 2020

E. End of Review: September 10, 2020

II. Recommendation

Evidence summary: http://bit.ly/ESECMO
Rapid review: http://bit.ly/RRevECMO

III. Decision

Decision of the Secretary of Health: http://bit.ly/DecisionECMO

 

HTAC Recommendation Preview: